Ethan Baughman, MD PhD FACS’ Post
3mo
The European peptide market is expanding rapidly — but it is not a regulatory free-for-all. In the EU, peptides intended for therapeutic use fall under medicinal product regulation governed by the EMA and national authorities. Only peptides with formal marketing authorization — such as insulin or GLP-1 receptor agonists — are approved for human use. Most so-called “longevity peptides” circulating online, including BPC-157, TB-500, epitalon, and GHK-Cu, do not hold EMA authorization and are often sold as “research use only,” despite being marketed for injection. At the same time, demand is being driven by telehealth expansion, biohacker culture, and the spillover credibility of GLP-1 success. Social media has amplified stacking trends and cross-border online distribution, creating a market that is scaling faster than regulatory clarity evolves. The EU framework itself is strong. If a peptide is intended to diagnose, prevent, or treat disease, it is a medicinal product under EU law. Claims, importation, compounding, and advertising are regulated. Risk emerges when companies blur those boundaries. The market now sits on a spectrum: fully authorized biologics, lawful magistral compounding, and research peptides marketed beyond regulatory authorization. It is the third category where enforcement, reputational exposure, and litigation risk are increasing. For investors and operators, this is not simply a wellness trend — it is a regulatory strategy question. Growth velocity without regulatory durability creates enterprise risk. VC firms and companies operating in peptide therapeutics, longevity platforms, telehealth, or compounding ecosystems should evaluate regulatory defensibility early — not after scale. I advise companies and investors navigating FDA and EMA frameworks, medical standard-of-care issues, and pharmaceutical compliance strategy. If your fund or company is building or mitigating risk in this space and seeking clinical and regulatory insight at the advisory level, I welcome a confidential discussion.
More from this author
Explore related topics
Explore content categories